title: An economic evaluation of sevelamer in patients new to dialysis.
abstract: OBJECTIVE
  The overall objective of this study was to estimate the costs and outcomes associated with treatment with sevelamer for hyperphosphataemia compared with calcium-based binders.
  
  
  METHODS
  Using published data on mortality and hospitalisation rates, a Markov model was developed to predict health outcomes and associated costs for the treatment of hyperphosphataemia using either sevelamer or calcium binders in chronic kidney disease patients who had recently started haemodialysis. Patient outcomes were modelled for 5 years, and incremental cost-effective ratios (ICERs) were calculated for sevelamer relative to calcium carbonate and calcium acetate binders. The perspective adopted was that of the UK National Health Service.
  
  
  RESULTS
  The total 5-year discounted treatment cost for patients treated with sevelamer is pound 24,216, while for the calcium carbonate group total cost was pound 17,695. This is an incremental cost of pound 6521 per sevelamer-treated patient over 5 years. Patients receiving sevelamer can be expected to experience 2.70 quality-adjusted life years (QALYs) compared to 2.46 for those treated with calcium carbonate (i.e. an incremental gain of 0.24 QALYs). This results in an incremental cost per QALY of pound 27,120 and an incremental cost per life year gained of pound 15,508. Results were similar with calcium acetate.
  
  
  CONCLUSIONS
  Together with the unique morbidity and mortality benefits, this study suggests that treatment with sevelamer confers clinical benefits with a modest investment of additional economic resources.
authors.affiliation: York Health Economics Consortium Ltd, University of York, UK. mt25@york.ac.uk
authors.forename: Matthew J
authors.initials: MJ
authors.lastname: Taylor
authors.forename: Heba A
authors.initials: HA
authors.lastname: Elgazzar
authors.forename: Stephen
authors.initials: S
authors.lastname: Chaplin
authors.forename: David
authors.initials: D
authors.lastname: Goldsmith
authors.forename: Donald A
authors.initials: DA
authors.lastname: Molony
mesh_terms: D000863:Antacids / Q000627:therapeutic use; D002119:Calcium Carbonate / Q000627:therapeutic use; D002614:Chelating Agents / Q000191:economics* / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D003661:Decision Support Techniques; D016527:Drug Costs; D006801:Humans; D054559:Hyperphosphatemia / Q000188:drug therapy* / Q000191:economics; D007676:Kidney Failure, Chronic / Q000628:therapy; D008390:Markov Chains; D011073:Polyamines / Q000191:economics* / Q000627:therapeutic use; D019057:Quality-Adjusted Life Years; D006435:Renal Dialysis; D000069603:Sevelamer
chemical_list: D000863:Antacids; D002614:Chelating Agents; D011073:Polyamines; D000069603:Sevelamer; D002119:Calcium Carbonate